JP6639483B2 - 神経保護効用のあるアマンタジン硝酸エステル化合物及びその調製と医療応用 - Google Patents

神経保護効用のあるアマンタジン硝酸エステル化合物及びその調製と医療応用 Download PDF

Info

Publication number
JP6639483B2
JP6639483B2 JP2017514763A JP2017514763A JP6639483B2 JP 6639483 B2 JP6639483 B2 JP 6639483B2 JP 2017514763 A JP2017514763 A JP 2017514763A JP 2017514763 A JP2017514763 A JP 2017514763A JP 6639483 B2 JP6639483 B2 JP 6639483B2
Authority
JP
Japan
Prior art keywords
compound
group
disease
ethyl acetate
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017514763A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017521482A5 (https=
JP2017521482A (ja
Inventor
ユーチアーン ワン
ユーチアーン ワン
ジュヨン リウ
ジュヨン リウ
ペイ ユー
ペイ ユー
イェウェイ スン
イェウェイ スン
ザイジュン ジャン
ザイジュン ジャン
ガオシャオ ジャン
ガオシャオ ジャン
ルーチェン シャン
ルーチェン シャン
プォン イー
プォン イー
ジェームス ラリック
ジェームス ラリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Magpie Pharmaceuticals Co Ltd
Original Assignee
Guangzhou Magpie Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Magpie Pharmaceuticals Co Ltd filed Critical Guangzhou Magpie Pharmaceuticals Co Ltd
Publication of JP2017521482A publication Critical patent/JP2017521482A/ja
Publication of JP2017521482A5 publication Critical patent/JP2017521482A5/ja
Application granted granted Critical
Publication of JP6639483B2 publication Critical patent/JP6639483B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C07C209/76—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by nitration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2017514763A 2014-05-29 2015-05-08 神経保護効用のあるアマンタジン硝酸エステル化合物及びその調製と医療応用 Active JP6639483B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410235747.5A CN105294450B (zh) 2014-05-29 2014-05-29 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用
CN201410235747.5 2014-05-29
PCT/CN2015/000314 WO2015180485A1 (zh) 2014-05-29 2015-05-08 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用

Publications (3)

Publication Number Publication Date
JP2017521482A JP2017521482A (ja) 2017-08-03
JP2017521482A5 JP2017521482A5 (https=) 2019-09-26
JP6639483B2 true JP6639483B2 (ja) 2020-02-05

Family

ID=54698036

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017514763A Active JP6639483B2 (ja) 2014-05-29 2015-05-08 神経保護効用のあるアマンタジン硝酸エステル化合物及びその調製と医療応用

Country Status (8)

Country Link
EP (1) EP3150574B1 (https=)
JP (1) JP6639483B2 (https=)
CN (3) CN118290279A (https=)
AU (1) AU2015267968B2 (https=)
CA (1) CA2950452C (https=)
ES (1) ES2946987T3 (https=)
IL (1) IL249242B (https=)
WO (1) WO2015180485A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106397119A (zh) * 2016-04-11 2017-02-15 上海博康精细化工有限公司 一种1，3-金刚烷二乙醇的制备方法
KR101659055B1 (ko) * 2016-05-10 2016-09-23 박소정 에피갈로카테킨 갈레이트 및 3,1-아다만탄디아세트산을 함유하는 알쯔하이머성 치매 치료 및 예방용 약학조성물
CN106344551B (zh) * 2016-08-22 2020-07-28 广州喜鹊医药有限公司 氨基金刚烷单硝酸酯类化合物在制备预防和治疗疾病药物中的应用
CN107412211A (zh) * 2017-08-04 2017-12-01 佛山喜鹊医药有限公司 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用
AU2018372938B2 (en) * 2017-11-22 2025-04-10 Panorama Research, Inc. Aminoadamantyl nitrate compounds and their use to treat CNS disorders
JP7296611B2 (ja) * 2018-08-03 2023-06-23 ビーエイチエヌ株式会社 一酸化窒素産生促進剤
CN109206317B (zh) * 2018-09-12 2021-07-09 青岛海蓝医药有限公司 一种金刚烷胺类硝酸酯衍生物的制备工艺
CN109172560B (zh) * 2018-10-15 2022-08-16 佛山喜鹊医药有限公司 氨基金刚烷硝酸酯类化合物或其药学上可接受的盐在预防和/或治疗肺部疾病中的应用
US20230218548A1 (en) * 2020-03-19 2023-07-13 Eumentis Therapeutics, Inc. Nitro-aminoadamantane compounds for the treatment of betacoronavirus infections
CN116725997A (zh) * 2022-03-01 2023-09-12 广州喜鹊医药有限公司 氨基金刚烷单硝酸酯类化合物在制药领域中的应用
CN117224520A (zh) * 2023-11-01 2023-12-15 广州喜鹊医药有限公司 (3-氨基-5-乙基金刚烷-1-基)硝酸甲酯及其药学上可接受的盐的医药用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
BR0116001A (pt) * 2000-12-07 2004-07-06 Neuromolecular Inc Métodos para tratar distúrbios neuropsiquiátricos com antagonistas receptores nmda
CN1125033C (zh) * 2001-08-29 2003-10-22 中国科学院广州化学研究所 美金刚胺盐酸盐的合成方法
CA2426492C (en) * 2002-05-31 2006-10-03 H. Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
CN1400205A (zh) * 2002-08-30 2003-03-05 中国科学院广州化学研究所 美金刚胺盐酸盐的制备方法
US20090088367A1 (en) * 2004-05-10 2009-04-02 Burnham Institute For Medical Research Treatment of Insulin Resistance/Metabolic Syndrome to Alleviate the Risks of Dementia
WO2007065036A2 (en) * 2005-12-02 2007-06-07 Neuromolecular Pharmaceuticals, Inc. Therapeutic conjugates and methods of using same
US9242009B2 (en) * 2012-07-17 2016-01-26 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases

Also Published As

Publication number Publication date
CN105294450A (zh) 2016-02-03
EP3150574A4 (en) 2017-11-22
AU2015267968A1 (en) 2016-12-15
CN105294450B (zh) 2024-05-17
EP3150574B1 (en) 2023-03-15
IL249242A0 (en) 2017-02-28
CN118239847A (zh) 2024-06-25
EP3150574A1 (en) 2017-04-05
AU2015267968B2 (en) 2018-05-17
WO2015180485A1 (zh) 2015-12-03
ES2946987T3 (es) 2023-07-31
CA2950452C (en) 2020-03-31
CA2950452A1 (en) 2015-12-03
CN118290279A (zh) 2024-07-05
JP2017521482A (ja) 2017-08-03
IL249242B (en) 2020-03-31

Similar Documents

Publication Publication Date Title
JP6639483B2 (ja) 神経保護効用のあるアマンタジン硝酸エステル化合物及びその調製と医療応用
FI95033B (fi) Menetelmä farmakologisesti aktiivisten 8-substituoitujen ksantiinijohdannaisten valmistamiseksi
CA3022482C (en) Arginase inhibitors and their therapeutic applications
JP6571756B2 (ja) 神経変性疾患に適応可能なインドリジン誘導体
EP3788039A1 (en) Factor xiia inhibitors
CN108530310A (zh) 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用
JP7442712B2 (ja) グリコシド化合物の誘導体からなる血管新生促進薬物を含有する予防薬
WO2010076033A1 (en) Toluidine sulfonamides and their use
US10214478B2 (en) Amantadine nitrate compounds with neural protective effect, and preparation and medical use thereof
CN106632245B (zh) 氮取代基苯基吡唑类黄嘌呤氧化还原酶抑制剂及制备与应用
AU2007327585B2 (en) Polymorphic forms of deferasirox ( ICL670A)
TR201809061T4 (tr) Nikotinik asetilkolin alıcının pozitif allosterik modülatörleri.
CN103626826B (zh) 含偶氮键的糖原磷酸化酶抑制剂胆酸类衍生物、其制备方法及医药用途
CN109810115B (zh) 异黄酮类化合物及其制备方法与应用
DE102005012681A1 (de) Neue 1,5-Dihydro-pyrrol-2-one
CN110078668B (zh) 一种苯基咪唑类xor抑制剂及制备与应用
CN119613419A (zh) 氘代的二芳基甘脲四聚体化合物及其用途
WO2014006120A1 (en) New positive allosteric modulators of nicotinic acetylcholine receptor
AU2020343737A1 (en) MAGL inhibitor, preparation method therefor and use thereof
CN117164566B (zh) 一种氧代哒嗪类化合物及其制备方法和用途
CN116283946B (zh) 5-(n-取代吲哚-5-基)异噁唑-3-甲酸衍生物及其合成方法和应用
CN121226285A (zh) 一种pde2/4双靶点抑制剂及其制备方法与应用
CN118894903A (zh) 一种氨基酸类化合物及其制备方法和医药应用
CN120309608A (zh) 一类含有杂环酰胺结构的化合物及其制备和用途
CN117545742A (zh) 嘧啶类化合物、包含其的药物组合物、其制备方法及其用途

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161129

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181116

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20181210

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190222

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20190806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191224

R150 Certificate of patent or registration of utility model

Ref document number: 6639483

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250